Incidence, risk factors, and outcomes of arterial thromboembolism in patients with pancreatic cancer following palliative chemotherapy

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Supportive Measures
Pancreatic Cancer
Presenter Wen-Chi Chou
Citation Annals of Oncology (2018) 29 (suppl_9): ix46-ix66. 10.1093/annonc/mdy432
Authors W. Chou1, Y. Chen2, J. Chen3, C. Lu4, P. Chang5, C. Hung6
  • 1Hematology And Oncology, Chang Gung Memorial Hospital-Linkou, 333 - Taoyuan/TW
  • 2Oncology And Hematology, Kaohsiung Chang Gung Memorial Hospital, 833 - Kaohsiung City/TW
  • 3Department Of Hematology And Oncology, Chang Gung Memorial Hospital, 333 - Taoyaun/TW
  • 4Hematology And Oncology, Chang Gung Memorial Hospital at Chiayi, Chiayi/TW
  • 5Medical Oncology, Chang Gung Memorial Hospital at Keelung, Keelung/TW
  • 6Medical Oncology, Mackay Memorial Hospital, Taipei/TW



Few studies have explored the association between pancreatic cancer and arterial thromboembolism (aTE). We aimed to determine the incidence, risk factors, and survival outcome of aTE in patients with pancreatic cancer.


A total of 838 consecutive patients, who received palliative chemotherapy for unresectable or metastatic pancreatic cancer between 2010 and 2016 from four institutes in Taiwan, were retrospectively enrolled. The clinical characteristics of patients were analyzed to identify independent predictors of aTE and survival outcome.


The median overall survival time was 7.7 months (range, 0.6–55.6); aTE occurred in 42 (5.0%) of 838 patients. Patients with aTE had a worse survival outcome than those without (5.1 months versus 7.8 months, hazard ratio 1.53, 95% confidence interval [CI]: 1.12–2.09). Stage IV disease, high aspartate transaminase level, and comorbidity with hypertension or atrial fibrillation were four independent predictors of aTE in multivariate analysis. A concise predictive model stratified patients into low (0–1 risk factor), intermediate (2 risk factors), and high (3–4 risk factors) risk groups. The hazard ratios for the comparison of patients in intermediate and high risk groups with those in low risk group were 4.55 (95% CI: 2.31–8.98), and 13.3 (95% CI: 5.63–31.6), respectively.


Patients with pancreatic cancer undergoing palliative chemotherapy have an increased risk of aTE. A predictive model showed that patients presented with 3 or 4 predictors had the highest risk for developing aTE. Further studies are needed to evaluate the performance of this predictive model.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Wen-Chi Chou.


Has not received any funding.


All authors have declared no conflicts of interest.